| abstract |
The invention provides compounds of formula (I), wherein R<1> and R<2> independently represent H or C1-6 alkyl; R<3> represents phenyl substituted by at least one group selected form halo, CF3, OCF3, CN, OH, C1-6 alkyl and C1-6 alkoxy; and R<4>, R<5> and R<11> independently represent H or -(CH2)n-A, wherein n represents 0, 1 or 2, provided that at least one of R<4>, R<5> and R<11> is other than H; A represents CONR<6>R<7> or SO2NR<6>R<7>, wherein R<6> and R<7> independently represent H, C3-6 cycloalkyl or C1-6 alkyl, the C<1-6> alkyl group being optionally substituted, in addition, R<6> and R<7> may, together with the N atom to which they are attached, represent a ring which is optionally substituted; CO2R<8>, wherein R<8> represents H or C1-6 alkyl; NR<9>R<10>, wherein R<9> and R<10> independently represent H, C1-6 alkyl (optionally substituted), (C1-6 alkyl)SO2-, (C1-6 alkyl)CO-, H2NSO2- or H2NCO-; a 5- or 6-membered heterocyclic ring containing 1, 2 or 3 heteroatoms selected from N, S and O, which is optionally substituted; S(O)x(C1-6 alkyl), wherein x represents 0, 1 or 2; OH; CN, NO2; or C1-6 alkoxy which is optionally substituted; provided that when NR<1>R<2> represents N(H) methyl, R<4> represents H and R<3> represents 4- chlorophenyl, then R<5> does not represent methoxy; and pharmaceutically acceptable salts thereof. The compounds of the invention are useful in the treatment or prevention of a variety of disorders, including those in which the regulation of monoamine transporter function is implicated. |